Analyst Insights: Celldex, InterMune, American Tower, Thermo Fisher, Jiayuan.com May 24th
Celldex Therapeutics, Inc. (NASDAQ:CLDX): Oppenheimer believes that data released by Celldex showed that the company’s CDX-011 drug benefited patients with a large amount of cancerous cells, as it’s designed to do. The firm doesn’t view the lack of response in other patients as negative for the company and it maintains a $6 target and Outperform rating on the stock.
InterMune Inc. (NASDAQ:ITMN): Canaccord said Beohringer’s BIBF-1120 may be approved in the U.S. before InterMune’s Esbriet and notes other companies have strong competitive pipelines. The firm reduced Esbriet peak sales estimates for 2025 to $2.1B from $3.6B and continues to rate shares a Buy.
American Tower Corp. (NYSE:AMT): Canaccord recommends using recent weakness in Buy rated American Tower (NYSE:AMT), Crown Castle (NYSE:CCI), and SBA Communications (NASDAQ:SBAC) as a buying opportunity. The firm expects carrier deployment of 4G LTE nationwide networks along with continued upgrade activity at Sprint (NYSE:S) and T-MobileUSA will be benefit to tower companies.
Thermo Fisher Scientific, Inc. (NYSE:TMO): Cowen said the risk/reward for Thermo Fisher is even more attractive following its analyst day. The firm cited expectations of improved earnings growth, increased market share, and management’s belief shares are undervalued. Shares are Outperform rated.
Jiayuan.com International Ltd (NASDAQ:DATE): Oppenheimer reduced its target on Jiayuan.com after the company reported lower than expected Q1 revenue. The firm believes that investors are likely to be disappointed with the company’s Q2 sales growth outlook, but it maintains an Outperform rating on the shares, citing strong gains in the company’s user base.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.